{
  "schema_version": "3.1.1-production",
  "doc_id": "CT-19852",
  "evaluation_id": "CT-19852",
  "extraction_date": "2022-06-15",
  "extraction_metadata": {
    "processing_version": "auto",
    "extraction_date": "2022-06-15",
    "parser": "auto",
    "annotateur_default": "auto",
    "niveau_confiance_default": 4,
    "source_files": {
      "F1": {
        "file_name": "ct_CT-19852_THIAMAZOLE_PIS_EUROGENERIQUE_AvisDèf_CT19852.pdf",
        "type": "CT",
        "page_count": 6
      }
    }
  },
  "template_detecte": "CT_modern",
  "section_taxonomy_version": "1.0",
  "SegmentIndex": [
    {
      "segment_id": "CT-19852_seg_1",
      "section_label_normalise": "SYNTHESE_DE_L_AVIS",
      "section_label_brut": "L’essentiel",
      "template_detecte": "CT_modern",
      "page_start": 1,
      "page_end": 1,
      "char_start": 0,
      "char_end": 500,
      "heading_text": "L’essentiel",
      "expected_fields": [
        "avis_favorable",
        "progres",
        "secteurs"
      ],
      "routing_hint": "Résumé",
      "label_confidence": 0.95,
      "evidence": []
    },
    {
      "segment_id": "CT-19852_seg_2",
      "section_label_normalise": "CONTEXTE",
      "section_label_brut": "Contexte",
      "template_detecte": "CT_modern",
      "page_start": 2,
      "page_end": 2,
      "char_start": 0,
      "char_end": 800,
      "heading_text": "Contexte",
      "expected_fields": [
        "demande_inscription",
        "reference_medicament",
        "amm_france",
        "historique_has"
      ],
      "routing_hint": "Contexte de l'évaluation",
      "label_confidence": 0.95,
      "evidence": []
    },
    {
      "segment_id": "CT-19852_seg_3",
      "section_label_normalise": "INDICATIONS_THERAPEUTIQUES",
      "section_label_brut": "Indication(s)",
      "template_detecte": "CT_modern",
      "page_start": 2,
      "page_end": 2,
      "char_start": 0,
      "char_end": 200,
      "heading_text": "Indication(s)",
      "expected_fields": [
        "indication_precise"
      ],
      "routing_hint": "Indication AMM",
      "label_confidence": 0.95,
      "evidence": []
    },
    {
      "segment_id": "CT-19852_seg_4",
      "section_label_normalise": "COMPARATEURS_PERTINENTS",
      "section_label_brut": "Comparateurs cliniquement pertinents",
      "template_detecte": "CT_modern",
      "page_start": 2,
      "page_end": 4,
      "char_start": 0,
      "char_end": 1500,
      "heading_text": "Comparateurs cliniquement pertinents",
      "expected_fields": [
        "comparateurs_medicamenteux",
        "comparateurs_non_medicamenteux"
      ],
      "routing_hint": "Comparateurs HAS",
      "label_confidence": 0.95,
      "evidence": []
    },
    {
      "segment_id": "CT-19852_seg_5",
      "section_label_normalise": "SERVICE_MEDICAL_RENDU",
      "section_label_brut": "Conclusions de la Commission",
      "template_detecte": "CT_modern",
      "page_start": 4,
      "page_end": 5,
      "char_start": 0,
      "char_end": 1200,
      "heading_text": "Conclusions de la Commission",
      "expected_fields": [
        "smr_enum",
        "asmr_enum",
        "impact_sante_publique",
        "avis_inscription",
        "taux_remboursement"
      ],
      "routing_hint": "Conclusions SMR/ASMR",
      "label_confidence": 0.95,
      "evidence": []
    },
    {
      "segment_id": "CT-19852_seg_6",
      "section_label_normalise": "POPULATION_CIBLE",
      "section_label_brut": "Population cible",
      "template_detecte": "CT_modern",
      "page_start": 4,
      "page_end": 5,
      "char_start": 0,
      "char_end": 600,
      "heading_text": "Population cible",
      "expected_fields": [
        "population_cible_description",
        "prevalence",
        "estimation_patients"
      ],
      "routing_hint": "Population cible",
      "label_confidence": 0.95,
      "evidence": []
    },
    {
      "segment_id": "CT-19852_seg_7",
      "section_label_normalise": "RECOMMANDATIONS",
      "section_label_brut": "Recommandations de la Commission",
      "template_detecte": "CT_modern",
      "page_start": 5,
      "page_end": 5,
      "char_start": 0,
      "char_end": 400,
      "heading_text": "Recommandations de la Commission",
      "expected_fields": [
        "conditionnement_recommandations"
      ],
      "routing_hint": "Recommandations",
      "label_confidence": 0.95,
      "evidence": []
    },
    {
      "segment_id": "CT-19852_seg_8",
      "section_label_normalise": "INFORMATIONS_ADMINISTRATIVES",
      "section_label_brut": "Informations administratives et réglementaires",
      "template_detecte": "CT_modern",
      "page_start": 5,
      "page_end": 6,
      "char_start": 0,
      "char_end": 1000,
      "heading_text": "Informations administratives et réglementaires",
      "expected_fields": [
        "calendrier_evaluation",
        "presentations",
        "demandeur",
        "listes",
        "amm",
        "conditions_prescription",
        "code_atc"
      ],
      "routing_hint": "Informations administratives",
      "label_confidence": 0.95,
      "evidence": []
    }
  ],
  "Identifiants_Produits_Liaison": [
    {
      "produit_id": "CT-19852_prod_1",
      "evaluation_id": "CT-19852",
      "produit_nom_commercial": "THIAMAZOLE UNI-PHARMA 5 mg",
      "forme_pharmaceutique": "comprimé sécable",
      "code_cip13": "34009 301 921 1 5",
      "code_cip13_2": "34009 301 921 2 2",
      "titulaire_amm": "EURODEP PHARMA",
      "evidence": [
        {
          "field": "code_cip13",
          "f": "F1",
          "p": 5,
          "s": "34009 301",
          "t": "100 comprimés sous plaquettes (PVC/Aluminium) (CIP : 34009 301 921 1 5)",
          "m": "rule",
          "c": 0.95
        },
        {
          "field": "code_cip13_2",
          "f": "F1",
          "p": 5,
          "s": "34009 301",
          "t": "125 comprimés sous plaquettes (PVC/Aluminium) (CIP : 34009 301 921 2 2)",
          "m": "rule",
          "c": 0.95
        }
      ]
    }
  ],
  "Evaluations_HAS": [
    {
      "evaluation_id": "CT-19852",
      "Num_avis": "CT-19852",
      "produit_nom": "THIAMAZOLE UNI-PHARMA 5 mg",
      "dci": "thiamazole",
      "type_avis": "Inscription",
      "type_avis_enum": "Inscription",
      "forme": "comprimé sécable",
      "dosage": "5 mg",
      "indication": "Traitement de l’hyperthyroïdie (thyrotoxicose) chez l’adulte, l’adolescent et l’enfant dès l’âge de 3 ans.",
      "classe_ATC": "H03BB02",
      "pathologie": "hyperthyroïdie",
      "maladie_rare": false,
      "ligne_traitement": "traitement de première intention",
      "ligne_traitement_enum": "1L",
      "sous_groupe_population": "Non renseigné",
      "cim10_principal": "Non renseigné",
      "cim10_secondaires": [],
      "libelle_cim10": "Non renseigné",
      "source_cim10": "Non renseigné",
      "aire_therapeutique_niveau_1": "Hormones systémiques, exclusions sexuelles",
      "aire_therapeutique_niveau_2": "Thyroïde",
      "aire_therapeutique_niveau_3": "Antithyroïdiens",
      "source_aire_therapeutique": "Déduit ATC H03BB02",
      "design_etude": "Non renseigné",
      "niveau_preuve_brut": "Non renseigné",
      "niveau_preuve_interprete": "Non renseigné",
      "besoin_medical_brut": "Non renseigné",
      "besoin_medical_interprete": "Non renseigné",
      "pathologie_categorie_enum": "Endocrinologie",
      "age_restriction_flag": true,
      "age_restriction_detail": "adulte, adolescent, enfant dès 3 ans",
      "biomarqueur_requis": "Aucun",
      "design_enum": "Non renseigné",
      "gravite_patho": "L’hyperthyroïdie peut être responsable de complications (cardiaques, psychiatriques, altération de l’état général) susceptibles d’engager le pronostic vital.",
      "gravite_patho_enum": [
        "Grave"
      ],
      "type_population_cible": "adultes, adolescents, enfants dès l’âge de 3 ans",
      "caractere_innovant_reconnu": false,
      "perte_de_chance_citee": false,
      "historique_Has_produit": "Non renseigné",
      "historique_ASMR_comparateurs": "Pour rappel, dans son avis du 13 mai 2009, la Commission a octroyé à THYROZOL 5 mg (thiamazole), un service médical rendu important et a jugé que cette spécialité n’apportait pas d’amélioration du service médical rendu (ASMR V) par rapport aux autres antithyroïdiens de synthèse disponibles.",
      "concurrence_therapeutique_recente": "Non renseigné",
      "vote_unanimite": null,
      "nb_votants": null,
      "nb_voix_pour": null,
      "nb_voix_contre": null,
      "nb_abstentions": null,
      "date_evaluation": "2022-06-15",
      "transcription_textuelle": "Non renseigné",
      "extraits_arguments": [],
      "evidence": [
        {
          "field": "indication",
          "f": "F1",
          "p": 2,
          "s": "Traitement",
          "t": "Traitement de l’hyperthyroïdie (thyrotoxicose) chez l’adulte, l’adolescent et l’enfant dès l’âge de 3 ans.",
          "m": "rule",
          "c": 0.95
        },
        {
          "field": "classe_ATC",
          "f": "F1",
          "p": 5,
          "s": "Code ATC",
          "t": "Code ATC H03BB02",
          "m": "rule",
          "c": 0.95
        },
        {
          "field": "gravite_patho",
          "f": "F1",
          "p": 4,
          "s": "L’hyperthyroïdie",
          "t": "L’hyperthyroïdie peut être responsable de complications (cardiaques, psychiatriques, altération de l’état général) susceptibles d’engager le pronostic vital.",
          "m": "rule",
          "c": 0.95
        }
      ]
    }
  ],
  "Essais_Cliniques": [],
  "Critères_Jugement": [],
  "Tolérance": [],
  "Comparateurs_Essai": [],
  "Comparateurs_HAS": [
    {
      "comparateur_id": "CT-19852_compHAS_1",
      "evaluation_id": "CT-19852",
      "nom_comparateur_HAS": "THYROZOL 5 mg, comprimé pelliculé (Thiamazole)",
      "type_comparateur": "Traitement_actif",
      "comparateur_standard_soin": "Oui",
      "famille_comparateur": "Antithyroïdiens_de_synthèse",
      "evidence": [
        {
          "field": "nom_comparateur_HAS",
          "f": "F1",
          "p": 2,
          "s": "THYROZOL",
          "t": "THYROZOL 5 mg, comprimé pelliculé (Thiamazole)",
          "m": "rule",
          "c": 0.95
        }
      ]
    },
    {
      "comparateur_id": "CT-19852_compHAS_2",
      "evaluation_id": "CT-19852",
      "nom_comparateur_HAS": "NEO-MERCAZOLE 5 mg, comprimé (carbimazole)",
      "type_comparateur": "Traitement_actif",
      "comparateur_standard_soin": "Oui",
      "famille_comparateur": "Antithyroïdiens_de_synthèse",
      "evidence": [
        {
          "field": "nom_comparateur_HAS",
          "f": "F1",
          "p": 3,
          "s": "NEO-MERCA",
          "t": "NEO-MERCAZOLE 5 mg, comprimé (carbimazole)",
          "m": "rule",
          "c": 0.95
        }
      ]
    },
    {
      "comparateur_id": "CT-19852_compHAS_3",
      "evaluation_id": "CT-19852",
      "nom_comparateur_HAS": "PROPYLEX 50 mg, comprimé (propylthiouracile)",
      "type_comparateur": "Traitement_actif",
      "comparateur_standard_soin": "Oui",
      "famille_comparateur": "Antithyroïdiens_de_synthèse",
      "evidence": [
        {
          "field": "nom_comparateur_HAS",
          "f": "F1",
          "p": 3,
          "s": "PROPYLEX",
          "t": "PROPYLEX 50 mg, comprimé (propylthiouracile)",
          "m": "rule",
          "c": 0.95
        }
      ]
    },
    {
      "comparateur_id": "CT-19852_compHAS_4",
      "evaluation_id": "CT-19852",
      "nom_comparateur_HAS": "BASDENE 25 mg, comprimé (benzylthiouracile)",
      "type_comparateur": "Traitement_actif",
      "comparateur_standard_soin": "Oui",
      "famille_comparateur": "Antithyroïdiens_de_synthèse",
      "evidence": [
        {
          "field": "nom_comparateur_HAS",
          "f": "F1",
          "p": 3,
          "s": "BASDENE",
          "t": "BASDENE 25 mg, comprimé (benzylthiouracile)",
          "m": "rule",
          "c": 0.95
        }
      ]
    },
    {
      "comparateur_id": "CT-19852_compHAS_5",
      "evaluation_id": "CT-19852",
      "nom_comparateur_HAS": "chirurgie",
      "type_comparateur": "Non_médicamenteux",
      "comparateur_standard_soin": "Oui",
      "famille_comparateur": "Chirurgie",
      "evidence": [
        {
          "field": "nom_comparateur_HAS",
          "f": "F1",
          "p": 3,
          "s": "Les comparateurs",
          "t": "Les comparateurs non médicamenteux de THIAMAZOLE UNI-PHARMA 5 mg (thiamazole) sont la chirurgie et l’iode radioactif (I-131).",
          "m": "rule",
          "c": 0.95
        }
      ]
    },
    {
      "comparateur_id": "CT-19852_compHAS_6",
      "evaluation_id": "CT-19852",
      "nom_comparateur_HAS": "iode radioactif (I-131)",
      "type_comparateur": "Non_médicamenteux",
      "comparateur_standard_soin": "Oui",
      "famille_comparateur": "Radiothérapie",
      "evidence": [
        {
          "field": "nom_comparateur_HAS",
          "f": "F1",
          "p": 3,
          "s": "Les comparateurs",
          "t": "Les comparateurs non médicamenteux de THIAMAZOLE UNI-PHARMA 5 mg (thiamazole) sont la chirurgie et l’iode radioactif (I-131).",
          "m": "rule",
          "c": 0.95
        }
      ]
    }
  ],
  "Arguments_Decisionnels": [],
  "Données_Contexte": {
    "contexte_id": "CT-19852_ctx",
    "evaluation_id": "CT-19852",
    "ISP": "Non renseigné",
    "acces_precoce": "Aucun",
    "date_debut_acces_precoce": "Non renseigné",
    "date_fin_acces_precoce": "Non renseigné",
    "duree_acces_precoce_mois": null,
    "nombre_patients_acces_precoce": null,
    "conditions_arret_acces_precoce": "Non renseigné",
    "ISP_flag": false,
    "ISP_categorie": "Pas_ISP",
    "type_acces_precoce_enum": "Aucun",
    "statut_reglementaire_ema": "AMM_standard",
    "date_AMM_ema": "2019-10-31",
    "date_avis_chmp": "Non renseigné",
    "innovation_therapeutique_ema": false,
    "designation_orpheline_ema": false,
    "prime_ema": false,
    "obligations_post_amm": [],
    "echeance_reexamen_amm": "Non renseigné",
    "nb_obligations_post_amm": null,
    "evaluation_internationale": "Non renseigné",
    "pays_evaluations": [],
    "decisions_internationales": [],
    "nb_decisions_internationales": null,
    "RDCR": "Non renseigné",
    "RDCR_num": null,
    "RDCR_intervalle": null,
    "RDCR_vs_seuil": "Non renseigné",
    "model_type": "Non renseigné",
    "perspective": "Non renseigné",
    "horizon_annees": null,
    "horizon_justification": "Non renseigné",
    "discount_rate_costs": null,
    "discount_rate_qalys": null,
    "DSA_flag": null,
    "PSA_flag": null,
    "scenario_analyses": [],
    "major_reserves": [],
    "nb_reserves_majeures": null,
    "impact_budgetaire_prevu": "Non renseigné",
    "impact_budgetaire_annee_1": null,
    "impact_budgetaire_annee_5": null,
    "impact_budgetaire_horizon": null,
    "hypothese_population_cible": null,
    "hypothese_penetration_marche_pct": null,
    "reserves_impact_budgetaire": [],
    "reserves_majeures": false,
    "population_cible_france": "La population cible de THIAMAZOLE UNI-PHARMA 5 mg (thiamazole) correspond aux adultes, adolescents et aux enfants de 3 ans et plus ayant une hyperthyroïdie (thyrotoxicose).",
    "population_cible_nombre": 1250200,
    "population_cible_intervalle": null,
    "source_estimation_population": "Extrapolation",
    "incertitude_population": "Élevée",
    "population_cible_mediane": null,
    "suivi_post_inscription": false,
    "nature_suivi_post_inscription": "Non renseigné",
    "delai_suivi_mois": null,
    "delai_suivi_justification": "Non renseigné",
    "conditions_suivi": "Non renseigné",
    "echeance_suivi": "Non renseigné",
    "impact_si_non_realise": "Non précisé",
    "delai_soumission_dossier": "Non renseigné",
    "delai_complement_demande": false,
    "dates_complement_demande": [],
    "delai_audition": false,
    "date_audition": "Non renseigné",
    "nb_total_reserves": null,
    "nb_total_reserves_mineures": null,
    "nb_totales_reserves_importantes": null,
    "nb_totales_reserves_majeures": null,
    "SMR_avant_audition_enum": "Non_renseigné",
    "SMR_apres_audition_enum": "Important",
    "ASMR_avant_audition_enum": "Non_renseigné",
    "ASMR_après_audition_enum": "V",
    "type_critère_justification": "Non renseigné",
    "valeur_critère": "Non renseigné",
    "impact_décision": "Non renseigné",
    "estimation_mesure_impact": "Non renseigné",
    "evidence": [
      {
        "field": "date_AMM_ema",
        "f": "F1",
        "p": 2,
        "s": "L’AMM a",
        "t": "L’AMM a été octroyée en France par procédure décentralisée le 31 octobre 2019",
        "m": "rule",
        "c": 0.95
      },
      {
        "field": "population_cible_nombre",
        "f": "F1",
        "p": 5,
        "s": "La prévalence",
        "t": "au maximum 1 250 200 patients auraient une hyperthyroïdie en 2022.",
        "m": "rule",
        "c": 0.95
      }
    ]
  },
  "Données_Textuelles": {
    "evaluation_id": "CT-19852",
    "texte_brut": "Non renseigné",
    "embedding": null,
    "evidence": []
  },
  "SMR_ASMR_Par_Indication": [
    {
      "smr_asmr_id": "CT-19852_smrasmr_01",
      "evaluation_id": "CT-19852",
      "indication_precise": "Traitement de l’hyperthyroïdie (thyrotoxicose) chez l’adulte, l’adolescent et l’enfant dès l’âge de 3 ans.",
      "smr": "La Commission considère que le service médical rendu par THIAMAZOLE UNI-PHARMA 5 mg (thiamazole) est important dans l’indication de l’AMM.",
      "smr_enum": "Important",
      "asmr": "Cette spécialité est un eurogénérique qui n’apporte pas d’amélioration du service médical rendu (ASMR V) par rapport aux autres antithyroïdiens de synthèse disponibles.",
      "asmr_enum": "V",
      "smr_revendique": "Non renseigné",
      "asmr_revendique": "Non renseigné",
      "asmr_revendique_enum": "Non_renseigné",
      "justification_decisionnelle": "Il s’agit d’un traitement de première intention des hyperthyroïdies.",
      "population_cible_indication": "adultes, adolescents, enfants dès 3 ans",
      "ligne_traitement_indication": "première intention",
      "comparateurs_references_indication": [
        "THYROZOL 5 mg",
        "NEO-MERCAZOLE 5 mg",
        "PROPYLEX 50 mg",
        "BASDENE 25 mg",
        "chirurgie",
        "iode radioactif (I-131)"
      ],
      "comparateur_id_HAS": [
        "CT-19852_compHAS_1",
        "CT-19852_compHAS_2",
        "CT-19852_compHAS_3",
        "CT-19852_compHAS_4",
        "CT-19852_compHAS_5",
        "CT-19852_compHAS_6"
      ],
      "indication_structuree": {
        "ligne_traitement": "1L",
        "biomarqueur": "Aucun",
        "stade": "Non renseigné",
        "population_age": "dès 3 ans"
      },
      "gain_survie_cite": false,
      "qol_cite": false,
      "tolerance_acceptable": true,
      "evidence_robustesse": "Non renseigné",
      "niveau_confiance_annotation": 4,
      "annotateur": "auto",
      "evidence": [
        {
          "field": "smr",
          "f": "F1",
          "p": 4,
          "s": "La Commission",
          "t": "La Commission considère que le service médical rendu par THIAMAZOLE UNI-PHARMA 5 mg (thiamazole) est important dans l’indication de l’AMM.",
          "m": "rule",
          "c": 0.95
        },
        {
          "field": "asmr",
          "f": "F1",
          "p": 4,
          "s": "Cette spécialité",
          "t": "Cette spécialité est un eurogénérique qui n’apporte pas d’amélioration du service médical rendu (ASMR V) par rapport aux autres antithyroïdiens de synthèse disponibles.",
          "m": "rule",
          "c": 0.95
        }
      ]
    }
  ],
  "Posologie_Par_Indication": [],
  "Timeline_Evenements": [
    {
      "event_id": "CT-19852_event_AMM_01",
      "evaluation_id": "CT-19852",
      "event_type": "AMM_EMA_DECISION",
      "event_date": "2019-10-31",
      "detail_brut": "AMM octroyée en France par procédure décentralisée",
      "source_doc": "F1",
      "detail_type_specifique": "Non renseigné",
      "acteurs_impliques": [],
      "duree_evenement_jours": null,
      "reference_externe": "Non renseigné",
      "delai_amm_ct_jours": 987,
      "delai_ct_jo_jours": null,
      "evidence": [
        {
          "field": "event_date",
          "f": "F1",
          "p": 2,
          "s": "L’AMM a",
          "t": "L’AMM a été octroyée en France par procédure décentralisée le 31 octobre 2019",
          "m": "rule",
          "c": 0.95
        }
      ]
    },
    {
      "event_id": "CT-19852_event_CT_01",
      "evaluation_id": "CT-19852",
      "event_type": "ADOPTION_CT",
      "event_date": "2022-06-15",
      "detail_brut": "Adopté par la Commission de la transparence",
      "source_doc": "F1",
      "detail_type_specifique": "Non renseigné",
      "acteurs_impliques": [],
      "duree_evenement_jours": null,
      "reference_externe": "Non renseigné",
      "delai_amm_ct_jours": null,
      "delai_ct_jo_jours": null,
      "evidence": [
        {
          "field": "event_date",
          "f": "F1",
          "p": 1,
          "s": "Adopté",
          "t": "Adopté par la Commission de la transparence le 15 juin 2022",
          "m": "rule",
          "c": 0.95
        }
      ]
    }
  ],
  "Timeline_Delais": {
    "evaluation_id": "CT-19852",
    "delai_amm_ct_jours": 987,
    "delai_transcription_ct_jours": null,
    "delai_audition_ct_jours": null,
    "complement_demande_mentionne": false,
    "audition_realisee": false,
    "evidence": []
  },
  "Features_Modele": {
    "evaluation_id": "CT-19852",
    "is_orphan": false,
    "classe_ATC_l2": "H03B",
    "aire_therapeutique": "Antithyroïdiens",
    "type_avis_enum": "Inscription",
    "innovation_reconnue": false,
    "perte_de_chance_citee": false,
    "ligne_traitement_num": 1,
    "is_rct": false,
    "n_essais": 0,
    "n_rct": 0,
    "presence_qol": false,
    "effet_principal_magnitude_num": null,
    "critere_principal_dur": false,
    "suivi_median_mois_max": null,
    "sae_pct_num": null,
    "discontinuations_pct_num": null,
    "critere_principal_description": "Non renseigné",
    "p_value_log10": null,
    "ceesp_present": false,
    "rdcr_num": null,
    "rdcr_log": null,
    "impact_budget_cat": "Non renseigné",
    "reserves_majeures": false,
    "nb_reserves_majeures": null,
    "vote_unanimite": null,
    "nb_votants": null,
    "voix_pour_pct": null,
    "association_patient_intervenue": false,
    "comparateur_placebo": false,
    "comparateur_soc": true,
    "nb_clockstops": 0,
    "annee_ct": 2022,
    "trimestre_ct": 2,
    "template_ere": "CT_modern",
    "missingness_indicators": [],
    "_meta": {}
  },
  "Relations": [
    {
      "src_type": "EVALUATION",
      "src_id": "CT-19852",
      "tgt_type": "PRODUIT",
      "tgt_id": "CT-19852_prod_1",
      "label": "EVAL_HAS_PRODUIT"
    },
    {
      "src_type": "EVALUATION",
      "src_id": "CT-19852",
      "tgt_type": "SMR_ASMR",
      "tgt_id": "CT-19852_smrasmr_01",
      "label": "EVAL_HAS_SMR_ASMR"
    },
    {
      "src_type": "EVALUATION",
      "src_id": "CT-19852",
      "tgt_type": "COMPARATEUR_HAS",
      "tgt_id": "CT-19852_compHAS_1",
      "label": "EVAL_HAS_COMPARATEUR"
    },
    {
      "src_type": "EVALUATION",
      "src_id": "CT-19852",
      "tgt_type": "COMPARATEUR_HAS",
      "tgt_id": "CT-19852_compHAS_2",
      "label": "EVAL_HAS_COMPARATEUR"
    },
    {
      "src_type": "EVALUATION",
      "src_id": "CT-19852",
      "tgt_type": "COMPARATEUR_HAS",
      "tgt_id": "CT-19852_compHAS_3",
      "label": "EVAL_HAS_COMPARATEUR"
    },
    {
      "src_type": "EVALUATION",
      "src_id": "CT-19852",
      "tgt_type": "COMPARATEUR_HAS",
      "tgt_id": "CT-19852_compHAS_4",
      "label": "EVAL_HAS_COMPARATEUR"
    },
    {
      "src_type": "EVALUATION",
      "src_id": "CT-19852",
      "tgt_type": "COMPARATEUR_HAS",
      "tgt_id": "CT-19852_compHAS_5",
      "label": "EVAL_HAS_COMPARATEUR"
    },
    {
      "src_type": "EVALUATION",
      "src_id": "CT-19852",
      "tgt_type": "COMPARATEUR_HAS",
      "tgt_id": "CT-19852_compHAS_6",
      "label": "EVAL_HAS_COMPARATEUR"
    }
  ],
  "Annotation_View": []
}